Seoochre

Polysaccharide derivatives are extensively used in chiral stationary phases. They provide multiple advantages including broad enantioselectivity, better resolution ability, easy availability, and high loadability under preparative separation conditions. Commercially available chiral stationary phases (CSPs) of this type are usually coated onto a silica matrix (or) covalently bonded to the silica matrix (immobilized). However, coated CSPs swell or dissolve and finally destroy the enantioselective capacity of the phase with some forbidden organic modifiers. The use of forbidden organic modifier

3D printing is a well-known additive manufacturing technique of the modern age. Since the first documentation of the process in 1980s Japan, 3D printing has entered many different fields, such as building construction, the arts and sports equipment. In healthcare, 3D printing has been used since the 1990s to manufacture dental implants and prosthetics, allowing for custom shape and size for each individual patient. More recently, 3D printing has entered the field of tissue engineering to build complex geometries out of novel biomaterials to mimic tissues. The use of 3D printing to manufactur

New technologies, advanced software systems, and the integration of IT within the pharma supply chain are increasingly playing a pivotal part in protecting pharmaceutical payloads worldwide.

Maintaining end-to-end pharma supply chain integrity is critical to mitigate risks within the pharma-logistics cool chain and better ensure the safe and secure transportation of health-giving and life-saving pharmaceutical products.

The global life sciences industry faces a number of complex challenges: protecting the integrity of their temperature-sensitive high-value payloads while mitigating cost

The pharmaceutical industry is expected to be worth $1.5 trillion by 2023, and the field of pharmacovigilance plays a crucial role in ensuring the safety of drugs. Artificial Intelligence (AI) and Machine Learning (ML) models are being applied to improve the pharmacovigilance process, including case intake using Optical Character Recognition (OCR) and Natural Language Processing (NLP), natural language generation (NLG) for narrative writing, robotic process automation (RPA) for dynamic case workflow, AI-based signal detection, and AI-based adverse event prediction. These advancements have the

The manufacturing process of pharmaceuticals has progressed from batch process to continuous process and now to printing.3D printing technology started gaining increased attention in the pharmaceutical field after the USFDA approval of the first 3D printed pill Spritam® by Aprecia Pharmaceuticals in 2015. This technology has been utilized for the printing of medical devices, dental implants, artificial organs, research prototypes, tailored dosage forms, drug fabrication, and specialty surgical instruments. It offers great flexibility which justifies its use in a wide range of settings includi

The top five drivers of this move to sustainability, according to the Packaging Sustainability: A Changing Landscape report from PMMI, The Association for Packaging and Processing Technologies, include brand perception, competitive pressure, environmental advocates, top-down company culture and good stewards of the planet. While a major focus for many, nearly two out of three brand owners participating in the PMMI report cited added cost as the top reason their sustainable packaging initiatives have slowed.

While the package is a vital part of any sustainability strategy, how the product g

In the ever-evolving realm of pharmaceutical research and development (R&D), the powerful wave of digitalization is restructuring conventional methodologies and paving the way for a novel era of ingenuity and streamlined processes. Termed digital transformation, this profound shift entails the strategic infusion of cutting-edge information technologies into established drug discovery and development procedures. Leading this revolution are technologies like big data analytics, artificial intelligence (AI), blockchain, and telemedicine. Digital transformation signifies a potential revolution in

The pharmaceutical market in Asia has undergone a paradigm shift in the past few years. The major global pharmaceutical companies have shifted their focus to this region to drive their revenue growth. Moreover, the domestic companies in Asia are also actively participating in the global drug development process. At present, the pharmaceutical market in the region is challenging due to changes in the competitive landscape, increasing R&D costs, and the need to develop the right marketing strategies.

In 2005, the pharmaceutical market in Asia was estimated to be around US$ 21 billion and is

Functional service has been ranked high among the buzz words of the clinical research industry. Both sponsor organisations and service providers are equally excited about the opportunities this model offers and the potentially win-win situation it provides to them. Sponsor organisations typically send individual protocol-related service RFPs (request for proposals) to CROs and follow-up with contract negotiations. Sponsors have realised the benefits of reduced oversight and contract management a complete functional service outsourcing model offers saving valuable time and resources. Depending

The pharmaceutical industry is in the midst of fundamental changes. The changes have been brought on by the increasing concerns over expiry of patents for major blockbuster drugs, weak product pipelines, heightened awareness of drug safety, globalisation, competition from generics and growing value considerations with regards to access to and reimbursement of new speciality therapeutics. These issues, and more, have forced top pharmaceutical companies to change their current course, in search of a stable and sustainable path that can help them maintain and improve their current profitability

There are many potential benefits that can be derived from IT outsourcing. Apart from cost savings, access to resources is also a driving force behind the outsourcing phenomena. With the right outsourcing partner enabling a flexible allocation of resources, IT projects can be scaled rapidly and affordably. Success or failure of outsourcing often has less to do with the provider and more to do with the customer. This is because discovery R&D organisations are rarely equipped to manage IT and have great difficulty specifying and implementing their goals. If any organisation has a poor track rec

Conventional dosage forms and delivery systems present several challenges in treatment of diseases like poor bioavailability, high dose, frequent administration, systemic adverse effects, etc. Also, increasing prevalence of chronic diseases, high demand for non-invasive administration of drugs, need for high bioavailability and targeted delivery of drugs for lesser side effects have paved the way for innovation in drug delivery systems. Therefore, pharmaceutical companies are focused on designing novel drug delivery systems to overcome the limitations of using conventional dosage forms. For t

The breakthrough in the search for a coronavirus vaccine highlights the speed with which the pharmaceutical industry can mobilise scientific ingenuity in the service of humankind’s core goals. Yet, industry leaders know that such speed is the exception to the norm. Here, John Young, APAC director at automation parts supplier EU Automation, looks at four areas where greater automation could have a significant impact in helping speed the process of bringing a new drug to market in the years ahead.

The question which confuses people many a times is: are generics and biologics the same? And the answer is no, they are not the same. Let’s find out how.

Biologics are basically the products which are developed and produced from living organisms like human, plant or animal cells and, of course, microorganisms (bacteria, yeast, etc.). Having no definite structure, biologics are large and complex molecules which undergo sophisticated procedures while being developed and manufactured. Monoclonal antibodies, hormones, enzymes, insulin, etc. can be referred to as biologics.

This article explores the transformative shift toward patient-centric clinical trials, emphasizing active patient involvement in study design, recruitment strategies, and the integration of Patient-Reported Outcomes (PROs). By prioritizing transparency, communication, and digital health technologies, patient-centric trials enhance engagement, streamline recruitment, and improve data quality. The approach holds the potential to accelerate drug development, but challenges like regulatory hurdles and data privacy concerns must be addressed collaboratively for widespread implementation.

In drug discovery, AI is being used to predict the efficacy and safety of potential drug candidates, identify new therapeutic targets, and optimize clinical trial designs. By harnessing the power of machine learning algorithms, researchers can analyze vast amounts of biological data and identify patterns that are difficult to discern using traditional methods.

In drug manufacturing, AI is being used to optimize manufacturing processes, reduce costs, and ensure quality control. AI-powered predictive models can analyze data from multiple sources to identify potential issues and optimize prod

The concepts of Big Data and Big Data Analytics have been around for some time but it has only been since the late 1990’s, with the confluence of genomic and transcriptomic data, along with increased use of EHR’s and access to claims data, that Big Data has arrived at the shores of pharma and healthcare. This rapid and accelerating access has been frequently represented by Hokusai’s tidal wave (Figure 1) but this metaphor may be hiding the real challenges that we need to face to deliver more effective diagnoses, drugs and patient outcomes. A potential evolution of this model, to embrace the

Pharmaceutical companies are faced with the challenge of effectively managing and analyzing large volumes of data, which come in various formats, in order to extract meaningful and actionable insights. This is crucial for efficient drug development that balances cost and effectiveness. The use of cutting-edge technologies can help uncover the mechanisms of diseases, optimize clinical trials, and improve production efficiency and accuracy. By utilizing data analytics and automation, pharmaceutical companies can optimize their manufacturing processes and ensure timely and reliable delivery of d

Nanomaterials have been one of the most exciting scientific and technical innovations of the past few decades. Due to their very high surface to volume ratios, they exhibit properties that can differ dramatically from those for the same material in bulk. This, and their ability to be designed and synthesized with multiple surface functionalities, has seen them used for a myriad of bespoke applications in industry and medicine.

Their medical applications span delivery systems for drugs, proteins and DNA/RNA to diagnostics, targeted cancer treatments, to theranostics. They have been used ver

Precision drugs need to be defined and validated as having the molecular structure that would interact with a precisely defined disease target. Further, it must exhibit the right pharmacokinetics to facilitate the drugs’ efficacy. Ideally, onand off-target interactions should not cause disabling adverse events.

Precision drugs are yet to be discovered and developed. Drug discovery often starts with a “shot in the dark.” A huge number of compounds are often “filtered” in silico before being examined using high throughput screening to identify potentially relevant active compounds that are s